Prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant Moraxella bovis cytotoxin-ISCOM matrix adjuvanted vaccine

John A Angelos, John F. Hess, Lisle W. George

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The efficacy of a recombinant Moraxella bovis cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK) was evaluated in a randomized, blinded, controlled field trial. Ninety-three cross bred beef calves were vaccinated with either saline, ISCOM matrix (adjuvant control), or a recombinant M. bovis cytotoxin carboxy terminus peptide plus ISCOM matrix and boostered 21 days later. Ocular examinations were performed once weekly for 20 weeks. At week 12, the cumulative proportion of calves with ulcerated eyes in the recombinant vaccine group was significantly lower than in the saline control group. Throughout the 20 week trial, the cumulative proportion of ulcerated calves remained lowest in the recombinant vaccine group. By week 7, nonulcerated calves in the recombinant vaccine group had significantly higher changes in serum neutralizing titers and cytotoxin specific to total IgG ratios in serum and tears as compared to calves in the control groups. The trend for a reduced cumulative proportion of IBK in the vaccinated calves over the 20 week trial suggests that a recombinant M. bovis cytotoxin vaccine may be beneficial in helping to prevent naturally occurring IBK.

Original languageEnglish (US)
Pages (from-to)537-545
Number of pages9
JournalVaccine
Volume23
Issue number4
DOIs
StatePublished - Dec 9 2004

Fingerprint

Infectious Keratoconjunctivitis
ISCOMs
Moraxella (Moraxella) bovis
Moraxella bovis
cytotoxins
keratoconjunctivitis
Cytotoxins
Synthetic Vaccines
Vaccines
calves
vaccines
cattle
recombinant vaccines
Control Groups
Subunit Vaccines
eyes
Serum
Tears
Immunoglobulin G
subunit vaccines

Keywords

  • Cytotoxin
  • ISCOM
  • Moraxella bovis

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant Moraxella bovis cytotoxin-ISCOM matrix adjuvanted vaccine. / Angelos, John A; Hess, John F.; George, Lisle W.

In: Vaccine, Vol. 23, No. 4, 09.12.2004, p. 537-545.

Research output: Contribution to journalArticle

@article{f41e360b215c4d02bd303a349e1f5969,
title = "Prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant Moraxella bovis cytotoxin-ISCOM matrix adjuvanted vaccine",
abstract = "The efficacy of a recombinant Moraxella bovis cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK) was evaluated in a randomized, blinded, controlled field trial. Ninety-three cross bred beef calves were vaccinated with either saline, ISCOM matrix (adjuvant control), or a recombinant M. bovis cytotoxin carboxy terminus peptide plus ISCOM matrix and boostered 21 days later. Ocular examinations were performed once weekly for 20 weeks. At week 12, the cumulative proportion of calves with ulcerated eyes in the recombinant vaccine group was significantly lower than in the saline control group. Throughout the 20 week trial, the cumulative proportion of ulcerated calves remained lowest in the recombinant vaccine group. By week 7, nonulcerated calves in the recombinant vaccine group had significantly higher changes in serum neutralizing titers and cytotoxin specific to total IgG ratios in serum and tears as compared to calves in the control groups. The trend for a reduced cumulative proportion of IBK in the vaccinated calves over the 20 week trial suggests that a recombinant M. bovis cytotoxin vaccine may be beneficial in helping to prevent naturally occurring IBK.",
keywords = "Cytotoxin, ISCOM, Moraxella bovis",
author = "Angelos, {John A} and Hess, {John F.} and George, {Lisle W.}",
year = "2004",
month = "12",
day = "9",
doi = "10.1016/j.vaccine.2004.06.025",
language = "English (US)",
volume = "23",
pages = "537--545",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant Moraxella bovis cytotoxin-ISCOM matrix adjuvanted vaccine

AU - Angelos, John A

AU - Hess, John F.

AU - George, Lisle W.

PY - 2004/12/9

Y1 - 2004/12/9

N2 - The efficacy of a recombinant Moraxella bovis cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK) was evaluated in a randomized, blinded, controlled field trial. Ninety-three cross bred beef calves were vaccinated with either saline, ISCOM matrix (adjuvant control), or a recombinant M. bovis cytotoxin carboxy terminus peptide plus ISCOM matrix and boostered 21 days later. Ocular examinations were performed once weekly for 20 weeks. At week 12, the cumulative proportion of calves with ulcerated eyes in the recombinant vaccine group was significantly lower than in the saline control group. Throughout the 20 week trial, the cumulative proportion of ulcerated calves remained lowest in the recombinant vaccine group. By week 7, nonulcerated calves in the recombinant vaccine group had significantly higher changes in serum neutralizing titers and cytotoxin specific to total IgG ratios in serum and tears as compared to calves in the control groups. The trend for a reduced cumulative proportion of IBK in the vaccinated calves over the 20 week trial suggests that a recombinant M. bovis cytotoxin vaccine may be beneficial in helping to prevent naturally occurring IBK.

AB - The efficacy of a recombinant Moraxella bovis cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK) was evaluated in a randomized, blinded, controlled field trial. Ninety-three cross bred beef calves were vaccinated with either saline, ISCOM matrix (adjuvant control), or a recombinant M. bovis cytotoxin carboxy terminus peptide plus ISCOM matrix and boostered 21 days later. Ocular examinations were performed once weekly for 20 weeks. At week 12, the cumulative proportion of calves with ulcerated eyes in the recombinant vaccine group was significantly lower than in the saline control group. Throughout the 20 week trial, the cumulative proportion of ulcerated calves remained lowest in the recombinant vaccine group. By week 7, nonulcerated calves in the recombinant vaccine group had significantly higher changes in serum neutralizing titers and cytotoxin specific to total IgG ratios in serum and tears as compared to calves in the control groups. The trend for a reduced cumulative proportion of IBK in the vaccinated calves over the 20 week trial suggests that a recombinant M. bovis cytotoxin vaccine may be beneficial in helping to prevent naturally occurring IBK.

KW - Cytotoxin

KW - ISCOM

KW - Moraxella bovis

UR - http://www.scopus.com/inward/record.url?scp=7944231466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7944231466&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2004.06.025

DO - 10.1016/j.vaccine.2004.06.025

M3 - Article

C2 - 15530703

AN - SCOPUS:7944231466

VL - 23

SP - 537

EP - 545

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 4

ER -